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from pluripotent stem cells by the use of soluble factors, can other human organs or tissues. However, by comparison to fresh
model human liver function and toxicity. However, at present
HLC maturity and whether any deﬁcit represents a true fetal state
or aberrant differentiation is unclear and compounded by com-
parison to potentially deteriorated adult hepatocytes. Therefore,
we generated HLCs from multiple lineages, using two different
protocols, for direct comparison with fresh fetal and adult
hepatocytes.
Methods: Protocols were developed for robust differentiation.
Multiple transcript, protein and functional analyses compared
HLCs to fresh human fetal and adult hepatocytes.
Results: HLCs were comparable to those of other laboratories by
multiple parameters. Transcriptional changes during differentia-
tion mimicked human embryogenesis and showed more similar-
ity to pericentral than periportal hepatocytes. UnbiasedJournal of Hepatology 20
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absolute quantiﬁcation; GSTp, glutathione S-transferase p.material, HLC maturity was proven by transcript, protein and
function to be fetal-like and short of the adult phenotype. The
expression of 81% phase 1 enzymes in HLCs was signiﬁcantly
upregulated and half were statistically not different from fetal
hepatocytes. HLCs secreted albumin and metabolized testoster-
one (CYP3A) and dextrorphan (CYP2D6) like fetal hepatocytes.
In seven bespoke tests, devised by principal components analysis
to distinguish fetal from adult hepatocytes, HLCs from two differ-
ent source laboratories consistently demonstrated fetal
characteristics.
Conclusions: HLCs from different sources are broadly compara-
ble with unbiased proteomic evidence for faithful differentiation
down the liver lineage. This current phenotype mimics human
fetal rather than adult hepatocytes.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatocyte-like cells (HLCs), differentiated from pluripotent
stem cells (PSCs), offer promise as in vitro models of human liver
development, function, and toxicity [1,2]. Most protocols have
attempted mimicry of embryogenesis through the addition of sol-
uble factors to the media. Activin A [3–13], alone or together with
Wingless-related integration site (Wnt) 3A [7–9,14,15], promotes
deﬁnitive endoderm (DE)-like differentiation. Fibroblast growth
factor (FGF) and bone morphogenetic protein (BMP) family15 vol. 62 j 581–589
Stage 1a/definitive endoderm-like: 2 days (→ DAY 2)
RPMI + 1 mM L-glutamine (L-G), 0.5% FBS,
Activin-A (Act-A) (100 ng/ml), Wnt3a (25 ng/ml)
Stage 1b/definitive endoderm-like: 2 days (→ DAY 4)
RPMI + 1 mM L-G, 0.5% FBS + Act-A (100 ng/ml)
Stage 2/hepatoblast-like: 6 days (→ DAY 10)
Hepatocyte culture medium (HCM)
Bmp2 (20 ng/ml) + Fgf4 (30 ng/ml)
Stage 3a/hepatocyte-like: 5 days (→ DAY 15)
HCM + Hgf (20 ng/ml)
Stage 3b/hepatocyte-like: 15 days (→ DAY 30)
HCM + Osm (10 μg/ml), dexamethasone (100 nM)
Fig. 1. The three-stage differentiation protocol. RPMI, Roswell Park Memorial
Institute; FBS, fetal bovine serum.
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members encourage hepatic differentiation [5,6,8,9,11–13]; and
hepatocyte growth factor (HGF), the synthetic glucocorticoid,
dexamethasone (DEX), and oncostatin M (OSM) support
increased maturity [3,4,6,8–14,16]. However, fully mature hepa-
tocytes have not been produced, which raises two unanswered
questions: are cells aberrant because human liver development
has not been followed with adequate speciﬁcity; or, if the lineage
is correct, are HLCs actually ‘stuck’ in a fetal-like state? Assess-
ment of the latter is problematic for two largely unaddressed rea-
sons. HLC maturity is over-estimated if compared to sub-optimal
adult hepatocytes. Thawed cells taken into culture are challeng-
ing to maintain [17]; in a well-controlled example, over 90% of
the cytochrome P450 (CYP) 3A activity was lost in cryopreserved
cells compared to freshly plated cells [18]. This illustrates the risk
of over-interpreting the HLC phenotype if compared against
dedifferentiated controls. Secondly, fresh fetal hepatocyte con-
trols have been lacking when assessing HLC function. This risks
misunderstanding as we have recently shown human fetal hepa-
tocytes possess proteins, such as CYP3A4, commonly interpreted
as adult markers [19].
To address these persisting questions about the differentiation
and maturity of HLCs, we implemented a protocol with sufﬁcient
commonality to allow comparisonwithmultiple previous reports.
We analysed a wide range of human ESC lines, derived under dif-
ferent conditions alongside H9 cells, the most popular line for
generating HLCs [3,7,9,10,12,14,18,20]. HLCs were assessed by
proteome analysis and in a series of assays against fresh human
fetal and adult hepatocytes. We also included cells differentiated
by a second protocol in an extended array of new tests for differ-
entiation status, devised by unbiased proteomics and principal
components analysis that distinguish fetal from fresh adult and
dedifferentiated adult hepatocyte phenotypes [19].Materials and methods
Human tissue and cells, and their culture
Human embryonic stem cell (ESC) lines were obtained with consent either
directly from the derivation laboratory or the UK Stem Cell Bank. Cells were
maintained on inactivated mouse embryonic ﬁbroblast (MEF) cells [21]. The dif-
ferentiation protocol (Fig. 1) was commenced 3–4 days post passage onto fresh
MEFs using Wnt3a (R&D Systems, UK) and Activin A (Peprotech, UK), diluted in
RPMI media (Sigma-Aldrich, UK); followed by BMP2, OSM, FGF2, HGF (all R&D
Systems) and DEX (Sigma-Aldrich, UK), diluted in Hepatocyte Culture Medium
(HCM) (Lonza, UK). Information on the human fetal and adult hepatocyte controls
can be found in the Supplementary Materials and methods. Human induced plu-
ripotent stem cells (IPSCs) were developed and differentiated as previously
reported [6,22].
Immunoblotting, immunoﬂuorescence, cell sorting and cell proliferation and apoptosis
studies
Immunoblotting and immunoﬂuorescence were conducted as previously
reported (Supplementary Table 1) [19,23]. Fluorescent activated cell sorting
(FACS), cell proliferation and apoptosis are described in Supplementary Materials
and methods.
Protein isolation and proteomic analysis
Protein isolation from whole cell extracts and labelling for isobaric tagging for
relative and absolute quantiﬁcation (iTRAQ) proteomics was described by Rowe
et al. [19]. Quantitation of proteins was relative to a common reference prepara-
tion included in each run across different experiments. Protein identiﬁcation and
interrogation are described in Supplementary Materials and methods.582 Journal of Hepatology 201Phenotypic analysis
Gene expression analysis by RNA sequencing (RNA-seq) and quantitative PCR is
described in Supplementary Materials and methods. Albumin and urea secretion
into the media was measured using a human albumin ELISA kit and the Quanti-
Chrom™ urea assay kit (both from Bethyl Laboratories). Comparisons with fetal
and adult hepatocyte data used the unpaired two-tailed Student’s t test. CYP3A
activity was assessed in duplicate by incubation with P450-Glo™ CYP3A4 assay
reagent (Luciferin-PFBE; Promega Ltd). For CYP analysis by mass spectrometry,
cells were incubated with 1 mM testosterone or 1 mM dextromethorphan (Sigma,
UK) in HCM. Conditioned medium was collected and diluted 1:1 in 0.5 lM phen-
acetin (Sigma) stop solution in methanol. CYP activity was calculated per min
incubation. Alcohol dehydrogenase activity of cell lysates was assessed using a
detection kit following the manufacturer’s instructions (Abcam, UK). Results were
standardized to the amount of protein measured by Bradford assay.Results
Differentiation of human ESCs to HLCs
Based on previous studies [3–16], iteration of a 3-stage protocol
(Fig. 1) was devised to differentiate a range of human ESC lines,
derived under diverse conditions to HLCs. During stage 1, Brachy-
ury protein was increased by Activin A on day 2–3, at and after
which FOXA2, GATA4 and SOX17 increased (Fig. 2A). However,
the low serum caused signiﬁcant cell death, which was prevented
by Wnt3A (25 ng/ml) for the ﬁrst two days of culture [7–9,14,15],
leading to robust detection of the three nuclear transcription fac-
tors by day 4 (Fig. 2B). FOXA2, SOX17, and GATA4 were detected
in >50% of cells for each ESC line, indicating a shared but variable
propensity for DE-like differentiation. More homogeneous differ-
entiation was observed in H9 cells (77–98% of cells positive for
FOXA2, SOX17, and GATA4) and HUES7 cells (84–96% cells posi-
tive for the three transcription factors) (Fig. 2C and Supplemen-
tary Fig. 1A). At the end of stage 2 (hepatoblast-like cells), 91%
of HUES7 and 98% of H9 derivatives contained AFP, of which at
least two-thirds clearly dual-stained for nuclear HNF4a
(Supplementary Fig. 1B and C; only robust HNF4a staining was
counted most likely underestimating the entire population of
HNF4a+/AFP+ cells). Approximately 25% of these AFP+ cells were5 vol. 62 j 581–589
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Fig. 2. Differentiation of ESCs to hepatocyte-like cells. (A) Immunoblotting of ESCs differentiated towards deﬁnitive endoderm (DE). (B) Inclusion of Wnt3A for stage 1a
improved detection of FOXA2, SOX17, and GATA4 by immunoblotting and immunoﬂuorescence at day 4 (DE). Size bar = 25 lm. (C). Mean percentage of cells by count
(± S.E.; numbers represented by the bar are shown below) that contained nuclear FOXA2, SOX17 or GATA4 either alone or in combination with NANOG at the end of stage 1.
(D) Brightﬁeld image of HLCs (H9 shown), compared to freshly plated human adult hepatocytes. Size bar = 150 lm. (E) Quantiﬁcation by cell counting (mean ± S.E.) of dual
immunoﬂuorescence for albumin and a1-antitrypsin (AAT) in the ﬁve human ESC lines. Example image is for the H9 lineage counterstained with DAPI. Size bar = 50 lm. (F)
Albumin secretion into the media (mean ± S.E. from >3 experiments) during differentiation compared to the secretion from equivalent numbers of freshly plated human
fetal and adult hepatocytes. n.s., no signiﬁcant difference between day 23 and day 30 for all lines (except HUES7 at day 30, ⁄p <0.05) and fetal hepatocytes. Values for all
lines except HUES8 (n.s.) were signiﬁcantly lower (p <0.05) than for adult hepatocytes.
JOURNAL OF HEPATOLOGYproliferating according to BrdU uptake over 4 h, with 10–15% in
apoptosis as detected by caspase-3 activity for both HUES7 and
H9 derivatives (Supplementary Fig. 1D).
Initial characterization of HLCs
Transcripts for albumin and alpha1-antitrypsin (AAT, ofﬁcially
designated SERPINA1) were barely identiﬁed in DE-like cells but
were readily detected in early HLCs following stage 3A (Supple-
mentary Fig. 2A and B). We have previously shown that the tran-
scription factors GATA4 and SOX17 become restricted from the
early human embryonic liver compared to the adjacent foregut
[23]. Between DE-like cells and early HLCs, GATA4, and SOX17
expression declined by approximately 75% and >90% respectively
(data not shown). The transcription factor HNF4a encoded by
HNF4A, is a master regulator of the hepatocyte phenotype [24–
26]. During development there is a switch from an upstream
immature P2 promoter to a downstream ‘liver’ P1 promoter, gen-
erating alternative ﬁrst exons of the HNF4A gene [27,28]. This was
mirrored in our cultures: in DE-like cells, HNF4A was expressed
from the ‘immature’ P2 promoter; however, in HLCs the down-
stream ﬁrst exon was preferentially transcribed from the P1
‘liver’ promoter (Supplementary Fig. 2C, red boxes).Journal of Hepatology 201Final HLC morphology mimicked that of freshly plated human
adult hepatocytes (Fig. 2D). Across the ﬁve different ESC lines,
albumin was present in >75% of differentiated H9, SHEF1 and
HUES7 cells (Fig. 2E). At least half of the H9 and HUES7
albumin-positive HLCs also contained AAT (Fig. 2E). All ﬁve cell
lines showed a progressive increase in albumin secretion starting
from day 11 (Fig. 2F). At the end of differentiation, levels were at
least comparable to those from freshly plated fetal hepatocytes,
which were approximately 8-fold lower than those from freshly
plated adult hepatocytes. HLCs also showed urea secretion
(mean ± S.E.: 2.87 ± 0.18 lg/ml/mg protein/day) comparable to
fresh fetal hepatocytes (2.71 ± 0.09 lg/ml/mg protein/day), but
approximately 18-fold lower than freshly plated adult cells
(50.6 ± 6.11 lg/ml/mg protein/day).
We wanted to assess whether HLCs mimic periportal or peri-
central hepatocytes. Glutamine synthase, a pericentral marker,
was readily detected by immunocytochemistry in contrast to car-
bamoyl-phosphate synthase, a periportal protein (Supplementary
Fig. 3A). This correlated to their transcript proﬁles (Supplemen-
tary Fig. 3B) and was true for a range of other genes, differentially
expressed between pericentral and periportal hepatocytes [29].
All the pericentral genes except UDP-glucuronosyltransferase
1A (UGT1A) were expressed at increased or equivalent levels to5 vol. 62 j 581–589 583
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Fig. 3. Proteins upregulated in HLCs characterize liver more than other human organs and tissues. Heatmap of the 61 proteins signiﬁcantly upregulated (>2-fold) in H9
HLCs compared to undifferentiated ESCs (Supplementary Table 2) analysed against gene expression experiments from a wide range of human organs and tissues, deposited
in the EMBL/EBI Gene Expression Atlas (GEA). The numbers in individual red or blue boxes represent the number of experiments deposited in the GEA database where the
gene, encoding that particular gene was up- (red) or downregulated (blue) in the relevant organ or tissue type.
Research Articlethose in DE-like cells. In contrast, only phosphoenolpyruvate car-
boxykinase 2 (PCK2) of the periportal markers was expressed in
HLCs, but at levels lower than in DE-like cells.
While these data were encouraging of liver-speciﬁc differenti-
ation, it is an assumption based on limited user-selected proteins
and assays and ignores potential similarity to cell types from
other organs. We performed unbiased proteomic assessment of
whole cell extracts from undifferentiated H9 cells and their HLCs
at the end of stage 3. 61 proteins showed signiﬁcant upregulation
(>2-fold) including known liver markers, such as AAT/SERPINA1
and phase 1 (e.g. aldehyde dehydrogenases) and phase 2 enzymes
(e.g., nicotinamide N-methyltransferase [NNMT] and glutathione
S-transferase [GST] Mu3) (Supplementary Table 2). Cytokeratin
(KRT) 8 and KRT18, both upregulated, function together as
heteropolymers to protect hepatocytes from mechanical and
non-mechanical stress [30]. KRT7, apparent in <10% of cells by
immunocytochemistry (data not shown), may reﬂect slight
permissiveness in our protocol to cholangiocyte differentiation
but has also been reported as a hepatocyte progenitor cell marker
[31,32]. Some upregulated proteins were not recognized as
hepatocyte markers, such as KRT5 and KRT6A. Therefore to assess
the broad proteome phenotype, we compared the upregulated
protein dataset against data from 30 other human organs and
tissues in the EBI Gene Expression Atlas (Fig. 3). By heatmap,
the upregulated HLC proteome most closely resembled the liver,584 Journal of Hepatology 201followed by another anterior derivative of foregut endoderm, the
thyroid. Other foregut endoderm derivatives (stomach, small
intestine and pancreas) showed recognizable similarity, in contrast
to a marked divergence of HLCs from mesodermal and ectodermal
derivatives such as bone marrow, skeletal muscle and brain.
HLCs have a metabolic proﬁle comparable to human fetal rather than
adult hepatocytes
To gain broad developmental insights iTRAQ was performed on
whole cell extracts rather than enriched microsomes. Conse-
quently, this restricted identiﬁcation of phase 1 enzymes, espe-
cially CYPs, similar to our previous study of human fetal and
adult hepatocytes [19]. We used quantitative RT-PCR to analyse
the expression of phase 1 enzymes, including CYPs (Fig. 4A), alco-
hol dehydrogenases (Fig. 4B), ﬂavin-containing monooxygenases
(Fig. 4C), aldehyde dehydrogenases (Fig. 4D), esterases (Fig. 4F),
and other enzymes (Fig. 4E). The expression of 51/63 enzymes
(81%) was signiﬁcantly increased in H9 HLCs and 30 (48%)
enzymes were signiﬁcantly increased in HUES7 HLCs compared
to their undifferentiated counterparts. CYP3A family members,
CYP1B1, and DPYD were clearly increased in HLCs (Fig. 4A) with
more modest increases in a number of alcohol dehydrogenases
and ﬂavin-containing monooxygenases (Fig. 4B and C). The
increase in the aldehyde dehydrogenase gene, ALDH1A1, in H95 vol. 62 j 581–589
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Research ArticleHLCs approached levels in fetal hepatocytes, while ALDH1A2
levels surpassed those of both adult and fetal cells (Fig. 4D).
However, more generally, HLC transcript levels were markedly
reduced compared to those in fresh human adult hepatocytes.
In contrast, expression of 33 of the 63 phase 1 enzymes in H9
HLCs (52%) was statistically either greater or no different than
in fresh human fetal hepatocytes, indicating a major overlap
between the HLC and fetal phase 1 metabolic phenotype.
CYP3A activity, mostly via CYP3A4 in adult liver, and CYP2D6
are two major mechanisms for drug metabolism that require
CYP oxidoreductase (CYPOR) to donate electrons during catalysis.
To help further gauge maturity of HLCs, we measured protein
levels by immunoblotting and metabolic activity by mass
spectrometry. Immunoreactivity for CYP3A (current antibodies
fail to distinguish the different CYP3A isoforms) in HLCs was
approximately 10% of the levels in fresh adult hepatocytes
(Fig. 5A). For CYP2D6, two closely positioned bands were visible,
the upper of which corresponded to the size of the puriﬁed protein
(Fig. 5A). CYPOR was robustly detected. CYP2D6 metabolizes
dextromethorphan to dextrorphan. This activity was detected in
both H9 and HUES7 HLCs, but not in ESCs or HepG2 cells.
Conversion by HUES7 HLCs was similar to that by fetal
hepatocytes but was 527-fold less than detected in fresh adult586 Journal of Hepatology 201hepatocytes (1313-fold lower than adult cells for H9 HLCs)
(Fig. 5B). CYP3A-mediated metabolism of testosterone to
6b-hydroxytestosterone by HLCs was at least 100-fold greater
than by ESCs or HepG2 cells and at least comparable to fresh fetal
hepatocytes (Fig. 5C). Nevertheless, CYP3A metabolism of
testosterone was 47-fold and 66-fold higher in fresh adult
hepatocytes than in HUES7 and H9 HLCs, respectively. Mass spec-
trometry provides a ‘gold standard’ for metabolic assay. In contrast,
our experience of measuring CYP3A4 activity by commercially
available luciferase assay (PFBE reagent, Promega) was unhelpful.
Although HLCs from all ﬁve ESC lines matched fresh fetal
hepatocytes, fetal hepatocytes misleadingly showed greater
activity than their adult counterparts (Supplementary Fig. 4).
Bespoke tests to distinguish hepatocyte maturity show that HLCs are
fetal-like
We have previously shown that CYP3A4 protein, detected by
iTRAQ, is relatively ineffective at determining hepatocyte matu-
rity or whether cells have dedifferentiated [19]. In contrast, prin-
cipal components analysis provided new protein combinations
and simple assays not requiring mass spectrometry to distinguish
human adult hepatocytes from their fetal counterparts: AFP,
GSTp and heat shock protein (HSP) 47 with negligible alcohol
dehydrogenase (ADH) activity or CYP2A6 discriminates fetal
cells; conversely, abundant CYP2A6 and ADH activity are hall-
marks of adult cells [19]. AFP, GSTp, and HSP47 were readily
detected in our HLCs (Fig. 6Aa and B). CYP2A6, another marker
of perivenous cells, was weakly detected in HLCs, which also
showed slightly more ADH activity than fetal cells (Fig. 6C); how-
ever, both CYP2A6 levels and ADH activity were much higher in
adult hepatocytes. Although our protocol has marked similarity
to that used widely by others [3–16], we wanted to extend these
discriminatory tests further by adding immunocytochemistry
and FACS analysis of HLCs differentiated from IPSCs by another
very well-established protocol in a different lab [6]. We also5 vol. 62 j 581–589
CYP2A6           AFP    GSTp HSP47
Freshly plated
human adult
hepatocytes
Dedifferentiated
human adult
hepatocytes
Freshly plated
human fetal
hepatocytes
HLCs
(human ESC 
derived)
HLCs
(human IPSC 
derived)
Fig. 7. Immunocytochemistry to discriminate hepatocyte maturity. Immuno-
ﬂuorescence for CYP2A6, AFP, GSTp, and HSP47 on freshly plated adult human
hepatocytes, dedifferentiated human adult hepatocytes, freshly plated human
fetal hepatocytes, and HLCs derived from human ESCs and from human IPSCs via
an alternative protocol [6]. Examples shown are from one set of experiments,
which were performed in triplicate on three separate cell preparations/differen-
tiations. Size bar represents 100 lm for all panels.
HLCs (human 
ESC derived)
Mouse
IgG
A
B
HSP47 AFP CYP2A6
Rabbit
IgG GSTp
HLCs (human 
IPSC derived)
Freshly plated 
human fetal 
hepatocytes
Freshly plated 
human adult 
hepatocytes
Dedifferentiated 
human adult 
hepatocytes
Freshly plated human 
fetal hepatocytes
HLCs (human ESC 
derived)
HLCs (human IPSC 
derived)
Freshly plated human 
adult hepatocytes
Dedifferentiated 
human adult 
hepatocytes
%
 o
f p
op
ul
at
io
n
  GSTp       HSP47        AFP      CYP2A6
100
50
0
Fig. 8. Flow cytometry analysis to discriminate hepatocyte maturity. (A) One
example of ﬂow cytometry experiments for CYP2A6, AFP, GSTp, and HSP47 with
their corresponding immunoglobulin control on freshly plated adult human
hepatocytes, dedifferentiated human adult hepatocytes, freshly plated human
fetal hepatocytes, and HLCs derived from human ESCs and from human IPSCs via
an alternative protocol [6]. These ﬂow cytometry experiments were each
performed on three separate preparations of each cell type. (B) Graph showing
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JOURNAL OF HEPATOLOGYexamined whether our markers could distinguish dedifferentiat-
ed adult hepatocytes from fetal-like immaturity. Although we
were unable to analyse ADH by immunocytochemistry, CYP2A6,
AFP, GSTp and HSP47 all gave the expected distribution in tripli-
cated samples of freshly plated human adult and fetal hepato-
cytes (Fig. 7). In contrast, minimal staining was apparent for
any of the markers in dedifferentiated adult hepatocytes. HLCs
from both sources produced fetal-like staining patterns with
few cells stained for CYP2A6. The corresponding proﬁles were
evident by FACS (Fig. 8). Taken together, these data consistently
indicate a fetal phenotype for HLCs.Discussion
Our differentiation of DE-like cells matched others in its sequen-
tial use of Activin A [3–13] and Wnt3A [7–9,14,15], FGF and BMP
signalling [5,6,8,9,11–13], HGF [3,4,8–13], and either OSM
[6,8,10,13,16] or dexamethasone [4,9] or both (this study and
[3,11,14]). Our chosen stem cell lines covered a range of deriva-
tion conditions with similar results from additional SHEF and
H1 lines (data not shown). H9 and HUES7 cells gave the highest
percentage of conversion to a hepatocyte-like phenotype similar
to that achieved by others, using H9 cells [3,7,9,10,12,14,18,20].
Four features of our data extend conﬁdence that our protocol,
and by inference others [3–16], mimic normal human liver devel-
opment. First, the downregulation of SOX17 and GATA4 expres-
sion between DE-like cells and HLCs (this study and [7,10,12])
complies with the exclusion of these transcription factors, which
we recently showed in human liver bud as it develops from theJournal of Hepatology 201foregut between 4 and 5 weeks post conception [23]. The high
rates of proliferation and apoptosis during this phase of differen-
tiation match those seen previously [25] and are consistent with
the major remodelling that characterizes embryogenesis. We
mimicked the change in HNF4A promoter usage during embry-
onic development [27,28]. Finally, despite some unexpected indi-
vidual proteins, we demonstrated that the HLC proteome had
more in common with human liver than any other organ tested.
These novel unbiased protein data complement a previous ‘liver-
speciﬁc’ transcriptome signature deﬁned in HLCs [10]. The latter
emanated from microarray analysis of multiple adult human tis-
sues [33]. ‘Liver-speciﬁc’ genes, such as albumin (ALB), various
CYPs, and AFP, can be expressed more widely than in liver [1].
Hence, there is reassurance from this ﬁrst proteomic approxima-
tion of HLCs to liver and related endoderm fates but not to major
ectoderm and mesoderm lineages.
Uncertainty on HLC maturity has been discussed by others
[16,20]; functional comparison with fresh fetal hepatocytes has
been lacking [6]. We included undifferentiated stem cells and
both fresh ﬁrst trimester fetal and adult hepatocytes and consis-
tently demonstrated major similarities with the fetal rather than
the adult cell type. Our data were consistent with a previous
report that included cryopreserved human fetal hepatocytes from
25 weeks of gestation [34]. Moreover, by studying fold incre-
ments over undifferentiated stem cells our data can be integrated5 vol. 62 j 581–589 587
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with those from others. Our fetal-like HLC albumin secretion
showed at least a 200-fold increase from the parent ESC line
(Fig. 2F). This increment matches or surpasses that reported by
others [3,9,11,18,22,35,36] but was still lower on average than
secretion from freshly plated adult cells. However, lower incre-
ments in albumin secretion from ESCs to HLCs have been
reported to match adult hepatocytes following cryopreservation
[35,36]. These data imply the ease with which adult control cells
can dedifferentiate and that in fact HLCs, differentiated through
the use of soluble factors, mimic human fetal cells in keeping
with the common AFP detection [3,5–7,9–12,14,16,22,37]. A sim-
ilar fetal-like conclusion can be drawn from urea secretion. Oth-
ers have observed relatively low urea secretion in HLCs compared
to adult cells [9,11,36], which may also reﬂect a pericentral rather
than a periportal phenotype [29].
H9 HLCs matched fetal hepatocytes for the expression of half
of the CYPs tested but were inferior for others (e.g. CYP2C8,
CYP3A, CYP4, and CYP7 family members, and CYP8B1). This
included transcripts for what have been previously considered
‘adult’ CYPs [6], warning that detection alone does not reliably
indicate maturity. Phase 1 enzyme expression was commonly
massively higher for fresh adult cells (up to 62,000-fold over ESCs
for CYP2E1). This was not apparent in a recent protocol [38], using
cryopreserved adult hepatocyte controls that had transcript lev-
els only approximately 20-fold higher than undifferentiated stem
cells for CYP2B6 (445-fold here), 10-fold for FMO3 (8178-fold
here), and 20-fold for CYP2A13 (664-fold here). The human fetal
liver contains both CYP3A4 and CYP2D6 proteins prior to mid-
gestation [19]. Here we showed fetal-like HLC function by mass
spectrometry, despite HLCs possessing between 10- and 60-fold
lower transcript levels than fetal hepatocytes for CYP3A4, CYP3A5,
and CYP3A7 (Fig. 6). Our experience with a commonly used com-
mercial ‘CYP3A4’ luciferase assay was misleading. Luciferase
CYP3A activity from HLCs was equivalent to data from others
[14] and to fetal hepatocytes; but fetal hepatocytes showed more
luciferase activity than adult hepatocytes, which is incompatible
with the approximate 100-fold superiority of adult cells by mass
spectrometry. Instead, we extended our previous discovery of a
signature of proteins, capable of distinguishing fetal from adult
hepatocytes [19]. Here, by adding immunocytochemistry and
FACS, the combination of CYP2A6, AFP, GSTp and HSP47 accu-
rately distinguished human fresh adult and fetal and dedifferen-
tiated adult hepatocytes. HLCs, generated by our main protocol
and another established one [6], possessed fetal discriminators
rather than an adult or a dedifferentiated phenotype.
In summary, our HLC differentiation, and by inference that of
others, mimics human liver development. However, by a wide
range of analyses, these HLCs share pronounced similarities
with human fetal rather than adult hepatocytes. This is important
as it implies currently elusive soluble factors require discovery
for the transition of HLCs in vitro into a truly mature adult
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